I believe VLA's directors are getting it right: the terms of the deal as announced are:
Column 1
0
The board of directors of Viralytics unanimously recommends that its company's shareholders vote in favour of the Scheme, subject to there being no superior proposal and an independent expert concluding that the Scheme is in the best interest of the company's shareholders. It is the intention of Viralytics directors to vote all the shares of Viralytics held or controlled by them in favour of the Scheme, subject to those same qualifications.
and:
Column 1
0
Implementation of the Scheme will be subject to customary conditions, including Viralytics shareholder approval, court approval, regulatory approval, an independent expert concluding, & continuing to conclude, that the Scheme is in the best interests of shareholders, and no material adverse change or prescribed event occurring,
Between now & the VLA shareholder meeting to approve the scheme on 28th May, 2018, there will likely be the Combo trial results we've been looking forward to. If they are sensational, then the "independent expert" would take those into consideration, & the clause "continuing to conclude" becomes very significant.
Congratulations on making the deal, as it stands
VLA Price at posting:
61.5¢ Sentiment: Hold Disclosure: Held
